Startup Funding Tracker
Home›People›Christopher Gagliardi
CG

Christopher Gagliardi

Director at AdvanCell. Also a director at Sudo Biosciences and i2O Therapeutics.

DirectorRoles at 3 startups
Christopher Gagliardi on LinkedIn
Updated Nov 10, 2026·Latest SEC filing Jul 16, 2026·Suggest an edit

About Christopher Gagliardi

Christopher Gagliardi is a director at AdvanCell.

Form D filings also name Christopher Gagliardi as a director at Sudo Biosciences and i2O Therapeutics.

Christopher Gagliardi first appears on SEC filings in 2020.

Experience

This experience comes from Christopher Gagliardi's profile and from SEC filings. For roles taken from filings, the years are when the filings name Christopher Gagliardi in the role, so the role may have started earlier or lasted longer.

Epicrispr Biotechnologies Current
Board Observer
2026 – Present
Diagonal Therapeutics Current
Board Observer
2026 – Present
QuantX Biosciences Current
Board Member
2025 – Present
Lifordi Immunotherapeutics, Inc. Current
Board Observer
2025 – Present
AdvanCell, Inc. Current
Director
2024 – Present · Cambridge, MA
Develops targeted radiation treatments for people with cancer.
Sudo Biosciences, Inc. Current
Director
2023 – Present · Carmel, IN
Avilar Therapeutics Current
Board Observer
2023 – Present
NextPoint Therapeutics, Inc. Current
Board Observer
2022 – Present
i2O Therapeutics, Inc. Current
Director
2020 – Present · Cambridge, MA
Minervax ApS Current
Board Member
2020 – Present
Sanofi Current
Principal, Sanofi Ventures
2017 – Present
Atalanta Therapeutics
Board Observer
2024 – 2026
Matchpoint Therapeutics
Board Observer
2022 – 2026
L.E.K. Consulting
Consultant
2015 – 2017
Graz University of Technology
Research Assistant/Intern, Department of Inorganic Chemistry
2006
Marine Biological Laboratory
Marine Resources Center
2005

Key Colleagues at Startups

The people Christopher Gagliardi works with at each company, as listed on that company's latest Form D.

AdvanCell, Inc. · Form D, Jul 16, 2026
AK
Andrew Kay
Director
PL
Philina Lee
Chief Executive Officer and director
JB
Jamil Beg
Director
KC
BM
WL
AA
Andrew Adamovich
Founder & Managing Director, Australia
AP
Aaron Pickett
Secretary
NE
AA
Sudo Biosciences, Inc. · Form D/A, Feb 15, 2024
EF
Edd Fleming
Director
DJ
SB
Scott Byrd
Chief Executive Officer and director
SF
DE
Daniel Estes
Director
i2O Therapeutics, Inc. · Form D, Oct 18, 2023
KG
Kurt Graves
Chief Executive Officer and director
AA

Sources

  1. SECAdvanCell, Inc. Form D, filed Jul 16, 2026
  2. SECSudo Biosciences, Inc. Form D/A, filed Feb 15, 2024
  3. SECi2O Therapeutics, Inc. Form D, filed Oct 18, 2023